Author's posts
ASC reimbursement rates shouldn't be based on ownership, leader says
According to Dennis Fliegelman, principal consultant at West Lake Village, Calif.-based ARA Financial Services, outpatient reimbursement should be based on clinical rationale rather than ownership structure.
Stark Law: What ASC leaders need to know in 2023
Becker’s has reported on three Stark Law changes and considerations in 2022. Here’s what ASC leaders need to know going into 2023:
Why this ASC leader questions CMS' 'methodology'
Dennis Fliegelman, principal consultant at West Lake Village, Calif.-based ARA Financial Services and former hospital administrator, joined Becker’s to discuss how CMS performed in 2022.
How physician pay changed in the last 5 years
Here are 29 physician specialties pay jumps in the last five years, according to Medscape’s 2018 and 2022 physician compensation reports:
Delaware clinic surpasses 100 TAVR procedures
Lewes, Del.-based Beebe Healthcare has completed its 100th transcatheter aortic valve replacement procedure, according to a Dec. 27 report from the Cape Gazette.
Cedars-Sinai welcomes 4 heart specialists
The Los Angeles-based Smidt Heart Institute at Cedars-Sinai has added four new heart specialists to its department of cardiology, including interventional cardiologist Aakriti Gupta, MD; electrophysiologists Eric Braunstein, MD, and Archana Ramireddy, …
Top supply leaders' plans for 2023 and 7 more supply chain updates
Here are eight supply chain updates for ASC leaders reported by Becker’s since Dec. 20:
Court OKs medical office building construction following eminent domain battle
Bowers Development will move forward with the construction of a medical office building in Utica, N.Y., following an eminent domain battle with the Oneida County Industrial Development Agency, according to a Dec. 27 report from WKTV.
Walgreens healthcare updates: 16 moves in 60 days
Sixteen Walgreens updates Becker’s has reported on since Oct. 18:
Opus Genetics acquires rights to two therapy products for retinal disease
Opus Genetics, a clinical-stage gene therapy company, has acquired the rights to two preclinical-stage AAV-based gene therapy products from Iveric Bio, a biopharmaceutical company.
